2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...